Newswise — (New York – November 5, 2018) Vascular specialists at the Icahn School of Medicine at Mount Sinai are the first in the United States to use the Eluvia™, a drug-eluting vascular stent system for clinical treatment of peripheral artery disease (PAD), a circulatory condition that causes a narrowing of the blood vessels and a reduction of blood flow to the limbs.
According to the U.S. Centers for Disease Control and Prevention, 8.5 million people in the country have PAD; men and woman are equally affected by the disease. PAD most commonly affects arteries in the legs and is caused by a buildup of plaque that restricts blood flow and causes pain and swelling. If left untreated, PAD can lead to gangrene and amputation.
Eluvia, a vascular stent system developed by Boston Scientific, is a polymer-coated stent that delivers drug therapy for 12 months, the time period when restenosis (narrowing of an artery after corrective procedure) is most likely to occur. As results showed in the IMPERIAL clinical trial, recently published in The Lancet, patients treated with the Eluvia stent experienced a greater 12-month primary patency (expansion of blood vessels) of 88.5 percent compared to 79.5 percent in patients treated with Zilver®PTX®, a competing stent system.
“Mount Sinai has been on the cutting edge of all new endovascular techniques and technology, and our institution was one of the first to use drug-eluting stents for the treatment of peripheral arterial disease,” said Robert Lookstein, MD, Professor of Radiology and Surgery and Vice Chair of the Department of Radiology. “Our team is excited to offer this new treatment to patients suffering from this terrible disease.”
Vascular and endovascular specialists at Mount Sinai perform thousands of endovascular procedures each year and offer a full range of minimally invasive therapies for peripheral vascular disease, including therapies for lower limb arterial circulation, venous disorders, and aneurysmal disease.
Dr. Lookstein receives compensation as an advisory board member and consultant to Boston Scientific.
About Mount Sinai Health System
The Mount Sinai Health System is New York City’s largest integrated delivery system encompassing seven hospital campuses, a leading medical school, and a vast network of ambulatory practices throughout the greater New York region. Mount Sinai’s vision is to produce the safest care, the highest quality, the highest satisfaction, the best access and the best value of any health system in the nation. The System includes approximately 6,600 primary and specialty care physicians; 11 joint-venture ambulatory surgery centers; more than 140 ambulatory practices throughout the five boroughs of New York City, Westchester, Long Island, and Florida; and 31 affiliated community health centers. The Icahn School of Medicine is one of three medical schools that have earned distinction by multiple indicators: ranked in the top 20 by U.S. News & World Report’s “Best Medical Schools”, aligned with a U.S. News & World Report’s “Honor Roll” Hospital, it is ranked as a leading medical school for National Institutes of Health funding, and among the top 10 most innovative research institutions as ranked by the journal Nature in its Nature Innovation Index. This reflects a special level of excellence in education, clinical practice, and research. The Mount Sinai Hospital is ranked No. 18 on U.S. News & World Report’s “Honor Roll” of top U.S. hospitals; it is one of the nation’s top 20 hospitals in Cardiology/Heart Surgery, Gastroenterology/GI Surgery, Geriatrics, Nephrology, and Neurology/Neurosurgery, and in the top 50 in six other specialties in the 2018-2019 “Best Hospitals” issue. Mount Sinai’s Kravis Children’s Hospital also is ranked nationally in five out of ten pediatric specialties by U.S. News & World Report. The New York Eye and Ear Infirmary of Mount Sinai is ranked 11th nationally for Ophthalmology and 44th for Ear, Nose, and Throat, while Mount Sinai Beth Israel, Mount Sinai St. Luke’s and Mount Sinai West are ranked regionally. For more information, visit http://www.mountsinai.org/, or find Mount Sinai on Facebook, Twitter and YouTube.
MEDIA CONTACTRegister for reporter access to contact details